Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04676906 | A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds | PHASE1 | COMPLETED | 18 | — | — | Nov 26, 2020 | Apr 28, 2021 | Apr 27, 2023 | 1 | Netherlands |
hours
| Arm | Type | Description |
|---|---|---|
| Study compound 1 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 1 |
| Study compound 2 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 2 |
| Study compound 3 | EXPERIMENTAL | Up to 6 volunteers will receive one dose of study compound 3 |
| Name | Type | Description |
|---|---|---|
| NNC0113-6861 | DRUG | Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861 |
| NNC0113-6860 | DRUG | Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860 |
| NNC0113-6891 | DRUG | Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891 |
Inclusion Criteria: * Healthy subject. * Sex : Male. * Age 18 to 54 years, inclusive, at the time of signing informed consent. * Body mass index (BMI) 18.0 to 30.0 kg/m\^2, inclusive, at the time of signing informed consent . Exclusion Criteria: * Known or suspected hypersensitivity to study prod...